Regarding the PAD setting, a comparison between the two drugs in terms of lower-limb complications has demonstrated more benefit with GLP-1 RA than SGLT2i, with such an increased risk of amputations in subjects on gliflozins [161,168]. The gene discussed is GLP1R; the disease is peripheral arterial disease.